Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases

By WebmasterNovember 12, 2020November 1st, 2024No Comments

Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases

See more here

Previous PostImmunome Reports Third Quarter 2020 Financial Results and Significant Progress
Next PostOssianix to Present Preclinical Data Demonstrating Best-in-Class Blood Brain Barrier Delivery in Non-Human Primates by Single Domain VNAR Antibodies

Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostImmunome Reports Third Quarter 2020 Financial Results and Significant Progress

Next PostOssianix to Present Preclinical Data Demonstrating Best-in-Class Blood Brain Barrier Delivery in Non-Human Primates by Single Domain VNAR Antibodies